Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Latest advances in precision medicine for prostate and bladder cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 788
Rating:

Prof Thomas Powles, Prof Matthew Galsky, Prof Bertrand Tombal

Professor Thomas Powles introduces a session on precision medicine in prostate cancer and bladder cancer at ESMO 2018 in Munich. He is joined by Dr Bertrand Tombal and Dr Matthew Galsky.

The conversation opens on the recent trial data announced at ESMO in which cabazitaxel was compared with abiraterone or enzalutamide in patients with poor prognosis metastatic castration-resistant prostate cancer (mCRPC).

Dr Tombal discusses availability of suitable biomarkers in prostate cancer, talking around why heterogeneity and the rarity of addressable mutations often make it difficult to predict response for these patients.

The experts also discussed advances in precision medicine for bladder cancer with a focus on immune checkpoint inhibitors; discussing results of keynote-057. The experts also discuss therapeutic options which delay the need for radical cystectomy in bladder cancer patients.

The conversation moves on to the use of biomarkers to predict therapeutic response in bladder cancer including DNA damage repair pathway proteins. The experts conclude by agreeing that there is a need to better define complete clinical response in bladder and prostate cancer to determine suitable treatment options for patients.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

22.11.18

no rating
Remembering Prof Arti Hurria

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation